The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1431
December 9, 2013
View Complete Issue         Table of Contents 2019 
Pertuzumab (Perjeta) for Preoperative Use in HER2-Positive Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pertuzumab (Perjeta) for Preoperative Use in HER2-Positive Breast Cancer
December 9, 2013 (Issue: 1431)
The FDA has approved the neoadjuvant (preoperative) use of pertuzumab (Perjeta – Genentech) in combination with trastuzumab (Herceptin) and docetaxel (Taxotere, and generics) for treatment of locally advanced, inflammatory, or early-stage HER2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pertuzumab (Perjeta) for Preoperative Use in HER2-Positive Breast Cancer
Article code: 1431c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.